Clinical Trials

Side effects of CAR T-cell therapy are dramatically reduced with new receptor

A new immunotherapy for lymphoma has been found to cause lower levels of neurologic toxicity than other T-cell therapies for lymphoma. The findings come from the first clinical test of a CAR T-cell therapy using a new anti-cancer T-cell receptor developed in the Center for Cancer Research.

Now recruiting: Combination therapy clinical trial for small-cell lung or small-cell extrapulmonary cancers

Anish Thomas, M.D., of the Developmental Therapeutics Branch, is leading a study of a drug combination to treat small-cell lung cancer that has come back after treatment as well as small-cell cancer that started at a site other than the lungs (extrapulmonary). Small-cell lung cancer is an aggressive, fast-growing type of lung cancer.

Clinical trial investigates IV administration of vaccine for advanced solid tumors

Marijo Bilusic, M.D., Ph.D., of the Genitourinary Malignancies Branch, is leading a clinical trial to test whether giving the MVA-BN-brachyury vaccine intravenously is safe for humans and has no intolerable side effects. The goal of the study is to see whether intravenous MVA-BN-brachyury vaccine can shrink tumors and slow or prevent the spread of cancer to other parts of the body.

FDA grants orphan drug designation to zotiraciclib for the treatment of glioma

The U.S. Food and Drug Administration granted orphan drug status in December to zotiraciclib for use in patients with glioma, a cancer of the brain that begins in glial cells (cells that surround and support nerve cells). This designation is based on results from an ongoing NCI-sponsored phase 1 trial led by the CCR Neuro-Oncology Branch at the NIH Clinical Center.

FDA grants orphan drug designation to zotiraciclib for the treatment of glioma

Jay Berzofsky and Hoyoung Maeng discuss new vaccine to help men with prostate cancer

Jay Berzofsky, M.D., Ph.D., Chief of the Vaccine Branch, and Hoyoung Maeng, M.D., Assistant Research Physician in the Vaccine Branch, recently discussed their ongoing work to design and develop vaccines and immunotherapy for cancer prevention and treatment with Cancer Therapy Advisor. They share how they are testing a vaccine that may one day delay the need to use androgen deprivation therapy (ADT) in prostate cancer patients.

Former Pediatric Oncology Branch patient donates toys to NIH Pediatric Clinic

In December, former patient Julie Jones donated over 1,000 toys to the Pediatric Clinic at the NIH Clinical Center. Jones is a former patient in the Pediatric Oncology Branch who was treated more than 20 years ago for alveolar rhabdomyosarcoma. She says, “I remember what it was like. What these children are going through at such a young age really breaks your heart. I’ve often said there’s nothing greater than seeing the smile on the face of a sick child.”

Clinical trial evaluates T-cell therapy for advanced mesothelin-expressing cancers

Some cancer cells express a higher-than-normal amount of mesothelin, which makes them more likely to multiply and spread to other parts of the body. Raffit Hassan, M.D., of the Thoracic and GI Malignancies Branch, is leading a trial that tests T-cell immunotherapy for patients with cancer of the lung and its lining, ovarian cancer and bile duct cancer that express high levels of mesothelin.

Clinical trial will test radiotracer imaging for high-risk localized prostate cancer

Many men with prostate cancer are diagnosed at an early stage of the disease when the cancer is confined to the prostate. However, about 20 percent are diagnosed with high-risk disease, which tends to spread, or metastasize, to other parts of the body. William Dahut, M.D., Senior Investigator in the Genitourinary Malignancies Branch, is leading a study using positron emission tomography/computed tomography (PET/CT) with radioactive material to try and identify places in the body where prostate cancer has spread.

Metastatic breast cancer survivor shares her clinical trial story

We’re celebrating breast cancer awareness month by sharing the story of Samantha Seinfeld, a metastatic breast cancer survivor who participated in a CCR first-in-human clinical trial over 10 years ago. Since then, she has remained cancer-free. Margaret Gatti-Mays, M.D., M.P.H., F.A.C.P., Assistant Research Physician in the Laboratory of Tumor Immunology and Biology, and James Gulley, M.D., Ph.D., Chief of the Genitourinary Malignancies Branch, are currently evaluating Samantha’s unusual immune response in hopes of improving the responses of other patients.

Breadcrumb